SAM #36C25727Q0058

VA NCO 17 intends to sole-source Signatera and Prospera molecular testing from Natera

VA Network Contracting Office 17 plans a sole-source contract with Natera for molecular testing at VA facilities in Texas. - Procuring agency: Department of Veterans Affairs, Network Contracting Office 17 (NCO 17), supporting facilities in VISN 17. - Contract approach: Intended sole-source, firm-fixed-price IDIQ contract with Natera, Inc.; this is a notice of intent, not a request for quotes. - Testing requested: 35 Signatera tests for molecular residual disease monitoring (CPT codes 81479 and 81455) and 25 Prospera transplant assessment tests (CPT code 81479). - Sole-source rationale: The notice states that Natera’s proprietary assays, technology, intellectual property, reagents, and bioinformatics platforms are not available from other laboratories or authorized distributors. - Potential responses: Interested parties may submit capability statements showing that they can provide an equivalent proprietary test. - Ordering and locations: The contract is expected to include five ordering periods. Individual orders will specify the VA service locations; exact performance dates are not stated.

Description

Special Notice

Special Notice

Page 3 of 3 Special Notice *= Required Field Special Notice

Page 1 of 3 1. NOTICE OF INTENT DESCRIPTION The Department of Veterans Affairs, Network Contracting Office (NCO) 17, located at 5441 Babcock Road, Suite 302, San Antonio, TX 78229, intends to award an Indefinite Delivery Indefinite Quantity (IDIQ) Firm Fixed Price contract with five ordering periods on a sole-source basis to: Natera, Inc. 13011 McCallen Pass Austin, TX 78752 This requirement is for proprietary molecular genetic reference testing services used in the evaluation and monitoring of transplant patients and cancer residual disease. 2. SUPPLIES/SERVICES Item 0001 Description: Signatera Only, CPT Codes 81479, 81455 Estimated Quantity: 35 Unit: Each Item 0002 Description: Prospera, CPT Code 81479 Estimated Quantity: 25 Unit: Each Natera is the sole provider of these proprietary medical laboratory tests, including: Prospera molecular expression transplant assessment test Signatera Residual Disease Test (MRD) (non liquid biopsy tumor typing) No other vendor possesses the proprietary methodologies, assays, or intellectual property required to perform these tests. 3. SOLE SOURCE JUSTIFICATION Testing required by the VA is proprietary to Natera, Inc. No authorized distributors, third party laboratories, or alternative clinical sources exist for the Prospera and Signatera MRD tests. These assays cannot be substituted or performed by any other laboratory. Only Natera maintains the necessary technology, reagents, and bioinformatics platforms. 4. THIS NOTICE IS NOT A REQUEST FOR QUOTES This Special Notice is issued solely for information and planning purposes. It does not constitute a solicitation or a request for competitive quotes. Interested parties may submit a capability statement demonstrating an ability to perform the required testing. Responses must clearly show that an equivalent proprietary test exists and can be provided. 5. RESPONSE INSTRUCTIONS Responses must be emailed to: Susan Flores Contract Specialist, NCO 17 Email: Susan.Flores2@va.gov

Deadline: November 2, 2026 at 10:00 AM CST

The Government will review all responses but retains discretion regarding whether to compete this requirement. The Government is not responsible for any costs incurred in responding to this notice.

1. PLACE OF PERFORMANCE VA Facilities within VISN 17 (Texas) Specific ordering locations will be identified in individual task/delivery orders.

2. PERIOD OF PERFORMANCE Five ordering periods (exact dates to be determined at award).

View original listing